Enoticumab

Drug Profile

Enoticumab

Alternative Names: Anti-Delta-Like Ligand 4 monoclonal antibody - Regeneron; Anti-DLL4 monoclonal antibody - Regeneron; REGN-421; SAR-153192

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Regeneron Pharmaceuticals; sanofi-aventis
  • Developer Regeneron Pharmaceuticals; Sanofi
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action DLL4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 31 Dec 2014 Discontinued - Phase-I for Solid tumours (Late-stage disease) in USA (IV) before December 2014 (Regeneron, Form 10-K, February 2015)
  • 31 Jul 2014 Sanofi opts out of co-development agreement for Enoticumab (ADNM)
  • 11 Mar 2014 Phase-I development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top